Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P55895
UPID:
RAG2_HUMAN
Alternative names:
-
Alternative UPACC:
P55895; A8K9E9; Q8TBL4
Background:
V(D)J recombination-activating protein 2 plays a pivotal role in the immune system's development by facilitating the V(D)J recombination process. This process is crucial for generating a diverse repertoire of immunoglobulin and T-cell receptor genes in B and T-lymphocytes. The protein's function in DNA cleavage and its interaction with chromatin structure underscore its importance in ensuring effective immune responses and maintaining genomic integrity.
Therapeutic significance:
Given its central role in immune system development, V(D)J recombination-activating protein 2 is implicated in several immunodeficiency diseases, including Combined cellular and humoral immune defects with granulomas, Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-positive, and Omenn syndrome. Understanding the protein's function and its genetic variants opens avenues for targeted therapies to correct immune system malfunctions and treat these life-threatening conditions.